Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    SYNB8802-CP-001
Previous Study | Return to List | Next Study

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04629170
Recruitment Status : Recruiting
First Posted : November 16, 2020
Last Update Posted : March 19, 2021
Sponsor:
Information provided by (Responsible Party):
Synlogic

Brief Summary:

This Phase 1a/b, first-in-human, multiple dose-escalation, randomized, double-blinded, placebo-controlled study is evaluating SYNB8802 in healthy volunteers (HV) and subjects diagnosed with enteric hyperoxaluria (EH). Eligible subjects receive investigational product (IP) and undergo safety monitoring, evaluations, and subsequent follow-up after IP administration.

In Part 2, all evaluations and assessments throughout this study may be conducted either at the clinical site or by a home healthcare professional at an alternative location (e.g., EH patient's home, hotel).


Condition or disease Intervention/treatment Phase
Healthy Enteric Hyperoxaluria Drug: SYNB8802 Drug: Placebo Phase 1

Detailed Description:

This study is evaluating the safety, tolerability, kinetics, and pharmacodynamics of SYNB8802 within the following 2 study parts:

Part 1 is an inpatient, placebo-controlled, multiple ascending dose (MAD) study in HV male and female subjects in up to 5 dose cohorts (6 treated: 3 placebo) for 5 days of dosing to identify the maximum tolerated dose (MTD).

Part 2 is a placebo-controlled crossover study in up to 20 adult male and female subjects with EH secondary to Roux-en-Y bariatric surgery. Subjects will be randomized to receive either SYNB8802 (at or below the MTD from Part 1) or placebo for six days before crossing over to receive either placebo or SYNB8802 for another six days, respectively. This part of the study has been designed with the flexibility of being able to be conducted either at the clinical site or by a home healthcare professional at an alternative location (e.g., patient's home, hotel).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 65 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Part 1 - randomized, placebo-controlled multiple-dose escalation Part 2 - randomized, placebo-controlled crossover
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Double-blind (Sponsor-open)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB8802 in Healthy Volunteers and in Patients With Enteric Hyperoxaluria
Actual Study Start Date : November 4, 2020
Estimated Primary Completion Date : August 16, 2021
Estimated Study Completion Date : September 13, 2021

Arm Intervention/treatment
Experimental: MAD HV: SYNB8802 (1 x 10^11 live cells)
HV subjects receive SYNB8802 (1 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
Drug: SYNB8802
SYNB8802 is formulated as a nonsterile solution intended for oral administration

Experimental: MAD HV: SYNB8802 (3 x 10^11 live cells)
HV subjects receive SYNB8802 (3 x 10^11 live cells) TID for 5 days in the MAD study (Part 1).
Drug: SYNB8802
SYNB8802 is formulated as a nonsterile solution intended for oral administration

Experimental: MAD HV: SYNB8802 (1 x 10^12 live cells)
HV subjects receive SYNB8802 (1 x 10^12 live cells) TID for 5 days in the MAD study (Part 1).
Drug: SYNB8802
SYNB8802 is formulated as a nonsterile solution intended for oral administration

Experimental: MAD HV: SYNB8802 (optional cohort 1)
HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
Drug: SYNB8802
SYNB8802 is formulated as a nonsterile solution intended for oral administration

Experimental: MAD HV: SYNB8802 (optional cohort 2)
HV subjects receive SYNB8802 (at a dose to be determined based on the data from the first 3 cohorts) TID for 5 days in the MAD study (Part 1).
Drug: SYNB8802
SYNB8802 is formulated as a nonsterile solution intended for oral administration

Placebo Comparator: MAD HV: Placebo
HV subjects receive placebo TID for 5 days in the MAD study (Part 1).
Drug: Placebo
In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder

Crossover Arm 1: SYNB8802 crossover to Placebo
In Part 2 subjects will be randomized (1:1) to receive SYNB8802 TID for 6 days and then, following a washout period, receive Placebo TID for 6 days.
Drug: SYNB8802
SYNB8802 is formulated as a nonsterile solution intended for oral administration

Drug: Placebo
In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder

Crossover Arm 2: Placebo crossover to SYNB8802
In Part 2 subjects will be randomized (1:1) to receive Placebo TID for 6 days and then, following a washout period, receive SYNB8802 TID for 6 days.
Drug: SYNB8802
SYNB8802 is formulated as a nonsterile solution intended for oral administration

Drug: Placebo
In order to maintain study blinding, matching placebo in identical packaging will be manufactured using an inactive powder




Primary Outcome Measures :
  1. Number of Subjects With Treatment-Emergent Adverse Events [ Time Frame: 33 Days ]

    Toxicity is graded in accordance with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. Adverse events (AEs) are reported based on clinical laboratory tests, vital signs, physical examinations, electrocardiograms, and any other medically indicated assessments from the time informed consent is signed through the end of the safety follow-up period.

    AEs are considered to be treatment emergent (TEAE) if they occur or worsen in severity after the first dose of study treatment. TEAEs are considered treatment-related if relationship to study drug is possibly related, probably related, or definitely related.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Part 1 Inclusion Criteria:

  1. Age ≥ 18 to ≤ 64 years.
  2. Body mass index (BMI) 18.5 to 28 kg/m2.
  3. Able and willing to voluntarily complete the informed consent process.
  4. Available for and agree to all study procedures, including feces, urine, and blood collection and adherence to diet control, inpatient monitoring, follow-up visits, and compliance with all study procedures.
  5. Male subjects who are sexually abstinent or surgically sterilized (vasectomy), or those who are sexually active with a female partner(s) and agree to use an acceptable method of contraception (such as a condom with spermicide) combined with an acceptable method of contraception for their non-pregnant female partner(s) (as defined in Inclusion Criterion # 6) after informed consent, throughout the study, and for a minimum of 3 months after the last dose of IMP, and who do not intend to donate sperm in the period from Screening until 3 months following administration of the investigational medical product.
  6. Female subjects who meet 1 of the following:

    1. Woman of childbearing potential (WOCBP) must have a negative pregnancy test (human chorionic gonadotropin) at Screening and at baseline prior to the start of IMP and must agree to use acceptable method(s) of contraception, combined with an acceptable method of contraception for their male partner(s) (as defined in Inclusion Criterion # 5) after informed consent, throughout the study and for a minimum of 3 months after the last dose of IMP. Acceptable methods of contraception include hormonal contraception, hormonal or non-hormonal intrauterine device, bilateral tubal occlusion, complete abstinence, vasectomized partner with documented azoospermia 3 months after procedure, diaphragm with spermicide, cervical cap with spermicide, vaginal sponge with spermicide, or male or female condom with or without spermicide.
    2. Premenopausal woman with at least 1 of the following:

    i. Documented hysterectomy ii. Documented bilateral salpingectomy iii. Documented bilateral oophorectomy iv. Documented tubal ligation/occlusion v. Sexual abstinence is preferred or usual lifestyle of the subject c. Postmenopausal women (12 months or more amenorrhea verified by follicle- stimulating hormone [FSH] assessment and over 45 years of age in the absence of other biological or physiological causes).

Part 1 Exclusion Criteria:

  1. Acute or chronic medical (including COVID-19 infection), surgical, psychiatric, or social condition or laboratory abnormality that may increase subject risk associated with study participation, compromise adherence to study procedures and requirements, or may confound interpretation of study safety or PD results and, in the judgment of the investigator, would make the subject inappropriate for enrollment.
  2. Body mass index (BMI) < 18.5 or > 28 kg/m2.
  3. Oxalobacter formigenes carrier.
  4. Pregnant (self or partner), or lactating.
  5. Unable or unwilling to discontinue vitamin C supplementation for the study duration.
  6. History of or current immunodeficiency disorder including autoimmune disorders and human immunodeficiency virus (HIV) antibody positivity.
  7. Hepatitis B surface antigen positivity (subjects with hepatitis B surface antibody positivity and hepatitis B core antibody positivity are not excluded, provided that the hepatitis B surface antigen is negative).
  8. Hepatitis C antibody positivity, unless a hepatitis C virus ribonucleic acid test is performed, and the result is negative.
  9. History of febrile illness, confirmed bacteremia, or other active infection deemed clinically significant by the investigator within 30 days prior to the anticipated first dose of IMP.
  10. History of (within the past month) passage of 3 or more loose stools per day; where 'loose stool' is defined as a Type 6 or Type 7 on the Bristol Stool Chart (see Appendix 1: Bristol Stool Chart).
  11. History of kidney stones, renal or pancreatic disease.
  12. GI disorder (including inflammatory or irritable bowel disorder of any grade and surgical removal of bowel sections) that could be associated with increased UOx levels.
  13. Active or past history of GI bleeding within 60 days prior to the Screening Visit as confirmed by hospitalization-related event(s) or medical history of hematemesis or hematochezia.
  14. Intolerance of or allergic reaction to EcN, esomeprazole or PPIs in general, or any of the ingredients in SYNB8802 or placebo formulations.
  15. Any condition (e.g., celiac disease, gastrectomy, bypass surgery, ileostomy), prescription medication, or over-the-counter product that may possibly affect absorption of medications or nutrients.
  16. Currently taking or plans to take any type of systemic (e.g., oral or intravenous) antibiotic within 30 days prior to Day 1 through the final day of inpatient monitoring. Exception: topical antibiotics are allowed.
  17. Major surgery (an operation upon an organ within the cranium, chest, abdomen, or pelvic cavity) or inpatient hospital stay within the past 3 months prior to Screening.
  18. Planned surgery, hospitalizations, dental work, or interventional studies between Screening and last anticipated visit that might require antibiotics.
  19. Taking or planning to take probiotic supplements (enriched foods excluded) within 30 days prior to Day -1 and for the duration of participation and follow-up.
  20. Dependence on alcohol or drugs of abuse.
  21. Administration or ingestion of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to Screening Visit; or current enrollment in an investigational study.
  22. Screening laboratory parameters (e.g., chemistry panel, hematology, coagulation) and ECG outside of the normal limits based on standard ranges, or as defined in the table below, or as judged to be clinically significant by the investigator. A single repeat evaluation is acceptable.

Part 2 Inclusion Criteria:

  1. Age ≥ 18 to ≤ 74 years.
  2. Able and willing to voluntarily complete the informed consent process.
  3. Available for and agree to all study procedures, including feces, urine, and blood collection and adherence to diet control, follow-up visits, and compliance with all study procedures.
  4. Enteric hyperoxaluria secondary to Roux-en-Y bariatric surgery (at least 12 months post-surgery).
  5. Urinary oxalate ≥ 70 mg/24 hours (mean of at least 2 urine collections during Screening).
  6. Male subjects who are sexually abstinent or surgically sterilized (vasectomy), or those who are sexually active with a female partner(s) and agree to use an acceptable method of contraception (such as condom with spermicide) combined with an acceptable method of contraception for their non-pregnant female partner(s) (as defined in Inclusion Criterion # 7) after informed consent, throughout the study, and for a minimum of 3 months after the last dose of IMP, and who do not intend to donate sperm in the period from Screening until 3 months following administration of the investigational medical product.
  7. Female subjects who meet 1 of the following:

    1. Woman of childbearing potential (WOCBP) must have a negative pregnancy test (human chorionic gonadotropin) at Screening and at baseline prior to the start of IMP and must agree to use acceptable method(s) of contraception, combined with an acceptable method of contraception for their male partner(s) (as defined in Inclusion Criterion # 6) after informed consent, throughout the study and for a minimum of 3 months after the last dose of IMP. Acceptable methods of contraception include hormonal contraception, hormonal or non-hormonal intrauterine device, bilateral tubal occlusion, complete abstinence, vasectomized partner with documented azoospermia 3 months after procedure, diaphragm with spermicide, cervical cap with spermicide, vaginal sponge with spermicide, or male or female condom with or without spermicide.
    2. Premenopausal woman with at least 1 of the following:

    i. Documented hysterectomy ii. Documented bilateral salpingectomy iii. Documented bilateral oophorectomy iv. Documented tubal ligation/occlusion v. Sexual abstinence is preferred or usual lifestyle of the subject c. Postmenopausal women (12 months or more amenorrhea verified by FSH assessment and over 45 years of age in the absence of other biological or physiological causes).

  8. Screening laboratory evaluations (e.g., chemistry panel, complete blood count with differential, prothrombin time [PT]/activated partial thromboplastin time [aPTT], urinalysis) and electrocardiogram (ECG) must be within normal limits or judged to be not clinically significant by the investigator.

Part 2 Exclusion Criteria:

  1. Acute or chronic medical (including COVID-19 infection), surgical, psychiatric, or social condition or laboratory abnormality that may increase subject risk associated with study participation, compromise adherence to study procedures and requirements, or may confound interpretation of study safety or PD results and, in the judgment of the investigator, would make the subject inappropriate for enrollment.
  2. Acute renal failure or eGFR < 45 mL/min/1.73 m2. A single repeat evaluation is acceptable.
  3. Unable or unwilling to discontinue vitamin C supplementation for the study duration.
  4. Diagnosis of primary hyperoxaluria or any other cause of hyperoxaluria.
  5. Oxalobacter formigenes carrier.
  6. Pregnant (self or partner), or lactating.
  7. Currently taking or plans to take any type of systemic (e.g., oral or intravenous) antibiotic within 30 days prior to Day 1 through the final safety assessment. Exception: topical antibiotics are allowed.
  8. Major surgery (an operation upon an organ within the cranium, chest, abdomen, or pelvic cavity) or inpatient hospital stay within the past 3 months prior to Screening.
  9. Planned surgery, hospitalizations, dental work, or interventional studies between Screening and last anticipated visit.
  10. Taking or planning to take probiotic supplements (enriched foods excluded) within 30 days prior to Day -1 and for the duration of participation.
  11. Intolerance of or allergic reaction to EcN, esomeprazole or PPIs in general, or any of the ingredients in SYNB8802 or placebo formulations.
  12. Dependence on alcohol or drugs of abuse.
  13. History of or current immunodeficiency disorder including autoimmune disorders and HIV antibody positivity.
  14. Hepatitis B surface antigen positivity (subjects with hepatitis B surface antibody positivity and hepatitis B core antibody positivity are not excluded, provided that the hepatitis B surface antigen is negative).
  15. Hepatitis C antibody positivity, unless a hepatitis C virus ribonucleic acid test is performed, and the result is negative.
  16. Administration or ingestion of an investigational drug within 30 days or 5 half-lives, whichever is longer, prior to Screening Visit; or current enrollment in an investigational study.
  17. History of bacteremia within 30 days prior to the anticipated first dose of IMP.
  18. History of inflammatory bowel disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04629170


Contacts
Layout table for location contacts
Contact: Andrew Marsh (617) 401-9975 Ext. 9135 andrew.marsh@synlogictx.com

Locations
Layout table for location information
United States, Arizona
Urological Associates of Southern Arizona (open to remote participation) Recruiting
Tucson, Arizona, United States, 85715
Contact: Jasmine Simpson    520-351-5583    jasmines@uasapc.com   
Contact: Christina Montijo    520-351-5582    christinam@uasapc.com   
Principal Investigator: Susan Kalota, MD         
United States, Florida
Genesis Clinical Research Recruiting
Tampa, Florida, United States, 33603
Contact: Layla Scalf    813-755-4400    lscalf@genesistrials.com   
Principal Investigator: Jesus Navarro, MD         
United States, Utah
PRA Health Sciences Recruiting
Salt Lake City, Utah, United States, 84124
Contact: Shawn Searle    801-904-4545    searleshawn@prahs.com   
Principal Investigator: Shawn Searle, MD         
Sponsors and Collaborators
Synlogic
Layout table for additonal information
Responsible Party: Synlogic
ClinicalTrials.gov Identifier: NCT04629170    
Other Study ID Numbers: SYNB8802-CP-001
First Posted: November 16, 2020    Key Record Dates
Last Update Posted: March 19, 2021
Last Verified: March 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No